Jun 2026 (Q2 FY26) — Aug 5, 2026
Charles River Laboratories Q2 FY26 — Strong DSA Bookings and Raised Full-Year Guidance
Read the full callCharles River Laboratories (CRL) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Charles River Laboratories earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,004 | −2.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 11.9 | +2.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -1.5 | −102.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
43 of 46 judged targets kept · 34 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Completion of the planned divestitures of non-core businesses | complete potential divestitures by the middle of 2026, covering businesses representing approximately 7% of 2025 revenue | Sep 2025 | we completed the divestitures of certain European discovery services sites in May 2026 as well as the CDMO and sell solutions businesses | Achieved |
| Second quarter sequential operating margin improvement in all three segments | all 3 segments will show a sequential improvement in operating margin | Mar 2026 | Operating margin declined by 80 basis points to 24.5% in the second quarter, due largely to the impact of lower sales volume and an unfavorable geographic revenue mix | Missed |
| Full-year consolidated organic revenue growth | down 1% to at least flat | Dec 2025 | We're also raising our organic revenue growth in the range of flat to a 1% increase, which represents a 150 basis point improvement to our prior guidance | Revised Up |
3 of CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s 80 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 77 more targets are in the full ledger.
Claimed
- DSA net book-to-bill rose to nearly 1.2x in Q2 FY26, the highest level in nearly 4 years and the third consecutive quarter above 1x.
- Total company organic revenue returned to growth at 0.1% year-over-year in Q2 FY26, marking the first increase since Q3 2023.
- Non-GAAP EPS of $3.02 in Q2 FY26 exceeded prior outlook, increasing 47% sequentially.
- Operating margin improved 420 basis points sequentially to 20.5% in Q2 FY26.
- Full-year organic revenue guidance was raised by 150 basis points to a range of flat to 1% increase.
Qualified
- RMS segment organic revenue declined 1.4% in Q2 FY26 due to lower small model volumes in North America and for research model services (GEMS).
- Unallocated corporate costs were higher than expected in Q2 FY26, totaling $72 million or 7.2% of revenue, partly due to deferred compensation plan market performance.
- Non-GAAP tax rate increased 110 basis points year-over-year to 23.8% in Q2 FY26, with the full-year outlook raised by 100 bps, creating a $0.20 EPS headwind.
Price
$300.02 −0.04% · −$0.13
Performance +68.1% 1Y
1Y: $178.52 on 17 Oct 2025 → $300.02. High $310.77 (5 Oct 2026), low $149.93 (18 May 2026).
- Previous close
- $300.15
- 52-week range
- $149.93 – $310.77
- One year
- +62.93%
Overview
- Symbol
- CRL
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
43 of 46 judged targets kept · 34 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Completion of the planned divestitures of non-core businesses | complete potential divestitures by the middle of 2026, covering businesses representing approximately 7% of 2025 revenue | Sep 2025 | we completed the divestitures of certain European discovery services sites in May 2026 as well as the CDMO and sell solutions businesses | Achieved |
| Second quarter sequential operating margin improvement in all three segments | all 3 segments will show a sequential improvement in operating margin | Mar 2026 | Operating margin declined by 80 basis points to 24.5% in the second quarter, due largely to the impact of lower sales volume and an unfavorable geographic revenue mix | Missed |
| Full-year consolidated organic revenue growth | down 1% to at least flat | Dec 2025 | We're also raising our organic revenue growth in the range of flat to a 1% increase, which represents a 150 basis point improvement to our prior guidance | Revised Up |
Claimed
- DSA net book-to-bill rose to nearly 1.2x in Q2 FY26, the highest level in nearly 4 years and the third consecutive quarter above 1x.
- Total company organic revenue returned to growth at 0.1% year-over-year in Q2 FY26, marking the first increase since Q3 2023.
- Non-GAAP EPS of $3.02 in Q2 FY26 exceeded prior outlook, increasing 47% sequentially.
- Operating margin improved 420 basis points sequentially to 20.5% in Q2 FY26.
- Full-year organic revenue guidance was raised by 150 basis points to a range of flat to 1% increase.
Qualified
- RMS segment organic revenue declined 1.4% in Q2 FY26 due to lower small model volumes in North America and for research model services (GEMS).
- Unallocated corporate costs were higher than expected in Q2 FY26, totaling $72 million or 7.2% of revenue, partly due to deferred compensation plan market performance.
- Non-GAAP tax rate increased 110 basis points year-over-year to 23.8% in Q2 FY26, with the full-year outlook raised by 100 bps, creating a $0.20 EPS headwind.
The full ledger
Open CHARLES RIVER LABORATORIES INTERNATIONAL, INC.’s full ledger
A free account opens 5 company ledgers a month. All 80 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 7, 2026
Charles River Laboratories Q1 FY26 — Strategic Initiatives Drive Margin Expansion Outlook
Read the full callEvery analysed call
Charles River Laboratories earnings calls (CRL)
Financials
What the filings say
Net profit, year on year: −103% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,010 | 1,003 | 984 | 1,032 | 1,005 | 994 | 996 | 1,004 |
| Operating profit | 117 | -168 | 75 | 100 | 134 | -283 | 120 | 120 |
| Operating margin | 11.6% | −16.7% | 7.6% | 9.7% | 13.3% | −28.5% | 12.0% | 11.9% |
| Interest | 30 | 28 | 28 | 30 | 25 | 24 | 27 | 30 |
| Net profit | 70 | -214 | 25 | 52 | 54 | -277 | -15 | -1 |
| EPS ($ per share) | 1.34 | — | 0.50 | 1.06 | 1.11 | — | -0.30 | -0.03 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| Reserves | 42 | 280 | 625 | 981 | 1,433 | 1,887 | 1,812 | 1,389 |
| Total liabilities | 2,518 | 3,026 | 3,347 | 4,432 | 4,579 | 4,536 | 4,020 | 3,924 |
| Fixed assets | 933 | 1,044 | 1,124 | 1,291 | 1,466 | 1,640 | 1,604 | 1,655 |
| Investments | 1 | 1 | 1 | 1 | — | — | — | — |
| Total assets | 3,856 | 4,693 | 5,491 | 7,024 | 7,603 | 8,195 | 7,528 | 7,135 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 441 | 481 | 547 | 761 | 620 | 684 | 735 | 738 |
| Cash from investing | -955 | -682 | -602 | -1,438 | -608 | -563 | -245 | -209 |
| Cash from financing | 558 | 232 | 47 | 673 | -42 | -86 | -551 | -537 |
| Net cash flow | 31 | 43 | -7 | 13 | -5 | 43 | -79 | 10 |
| Capital expenditure | -140 | -141 | -167 | -229 | -325 | -319 | -233 | -219 |
| Free cash flow | 301 | 340 | 380 | 532 | 295 | 365 | 502 | 518 |
CRL revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Discovery and Safety Assessment | 61% | — | 60% | 60% | 60% | 60% | 60% | 60% | -1.9% |
| Research Models and Services | 20% | 20% | 22% | 21% | 21% | 21% | 21% | 21% | -1.8% |
| Manufacturing Support | — | — | 18% | 19% | 19% | 20% | 19% | 19% | -6.3% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
CRL operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Backlog DSA | $1.92BAs previously mentioned, we are encouraged that the overall DSA demand environment is tracking to our expectation, resulting in a net book-to-bill of 1.04x and a slight sequential increase in backlog to $1.92 billion at the end of the first quarter.Source: earnings call transcript | $1.97BNet bookings increased significantly year-over-year and by 12.6% sequentially to $701 million in the second quarter resulting in an increase in the DSA backlog to $1.97 billion and a net book-to-bill of 1.9x.Source: earnings call transcript | +2.6% |
| Net bookings | $622MNet bookings totaled a solid $622 million, remaining above the $600 million threshold, driven by continued strength from our small and mid-sized biotech client base.Source: earnings call transcript | $701MNet bookings increased significantly year-over-year and by 12.6% sequentially to $701 million in the second quarter resulting in an increase in the DSA backlog to $1.97 billion and a net book-to-bill of 1.9x.Source: earnings call transcript | +12.7% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Revenue by region
Q2 FY2026 · share of revenue
- US 54% ↓ 2 pt
- Europe 26%
- CA 13%
- Asia Pacific 6% ↑ 2 pt
- Other 1%
As CRL cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
115 filings between Nov 6, 2025 and Oct 5, 2026.
Open market
decisions to buy or sellPurchases
$7.3K
2 purchases by 2 insiders
Sales
$42.91M
19 sales by 6 insiders
42% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 33
- Award — granted as compensation
- 12
- Option exercise — converted options into shares
- 32
- Tax withheld — shares kept back by the company to cover tax
Also filed: 17 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| FOSTER JAMES C | — | $34.84M | Aug 25, 2026 |
| Parisotto Shannon M | — | $3.27M | Oct 5, 2026 |
| Girshick Birgit | — | $1.82M | Aug 11, 2026 |
| Knell Michael Gunnar | — | $1.73M | Aug 6, 2026 |
| Creamer Victoria L | — | $1.08M | Aug 6, 2026 |
| Andrews Nancy C | — | $163.4K | Aug 18, 2026 |
| LaPlume Joseph W | $4.4K | — | Mar 3, 2026 |
| Coleman Glenn | $3.0K | — | Sep 30, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Option exercise 10b5-1 plan | 981 | $204.5K |
| Oct 5, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Sale 10b5-1 plan | 981 | $302.6K |
| Sep 30, 2026 | Coleman Glenn EVP & Chief Financial Officer | Purchase | 10 | $3.0K |
| Aug 25, 2026 | FOSTER JAMES C Director | Option exercise 10b5-1 plan | 21,132 | $4.10M |
| Aug 25, 2026 | FOSTER JAMES C Director | Option exercise 10b5-1 plan | 12,429 | $2.59M |
| Aug 25, 2026 | FOSTER JAMES C Director | Sale 10b5-1 plan | 33,561 | $10.07M |
| Aug 19, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Option exercise 10b5-1 plan | 2,039 | $395.8K |
| Aug 19, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Sale 10b5-1 plan | 2,039 | $599.7K |
| Aug 19, 2026 | Girshick Birgit Chief Executive Officer | Gift | 528 | $0 |
| Aug 18, 2026 | Andrews Nancy C Director | Option exercise | 573 | $94.1K |
| Aug 18, 2026 | Andrews Nancy C Director | Sale | 573 | $163.4K |
| Aug 11, 2026 | Girshick Birgit Chief Executive Officer | Option exercise 10b5-1 plan | 6,500 | $1.17M |
| Aug 11, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Option exercise 10b5-1 plan | 3,714 | $667.3K |
| Aug 11, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Sale 10b5-1 plan | 3,714 | $1.04M |
| Aug 11, 2026 | Girshick Birgit Chief Executive Officer | Sale 10b5-1 plan | 6,500 | $1.82M |
| Aug 10, 2026 | FOSTER JAMES C Director | Option exercise 10b5-1 plan | 28,733 | $5.16M |
| Aug 10, 2026 | LaPlume Joseph W EVP, Corp Strategy & Develop | Gift | 257 | $0 |
| Aug 10, 2026 | FOSTER JAMES C Director | Sale 10b5-1 plan | 28,733 | $7.90M |
| Aug 6, 2026 | Knell Michael Gunnar SVP, Finance and CAO | Sale | 1,274 | $330.1K |
| Aug 6, 2026 | Creamer Victoria L EVP & Chief People Officer | Option exercise | 4,179 | $750.8K |
| Aug 6, 2026 | Knell Michael Gunnar SVP, Finance and CAO | Sale | 404 | $104.4K |
| Aug 6, 2026 | Knell Michael Gunnar SVP, Finance and CAO | Sale | 1,205 | $311.5K |
| Aug 6, 2026 | Creamer Victoria L EVP & Chief People Officer | Sale | 4,179 | $1.08M |
| Aug 6, 2026 | Knell Michael Gunnar SVP, Finance and CAO | Option exercise | 736 | $153.4K |
| Aug 6, 2026 | Knell Michael Gunnar SVP, Finance and CAO | Option exercise | 1,205 | $233.9K |
| Aug 6, 2026 | Knell Michael Gunnar SVP, Finance and CAO | Sale | 736 | $190.3K |
| Aug 6, 2026 | Knell Michael Gunnar SVP, Finance and CAO | Option exercise | 404 | $72.6K |
| Aug 6, 2026 | Knell Michael Gunnar SVP, Finance and CAO | Sale | 482 | $127.8K |
| Aug 6, 2026 | Knell Michael Gunnar SVP, Finance and CAO | Sale | 620 | $163.6K |
| Aug 6, 2026 | Knell Michael Gunnar SVP, Finance and CAO | Sale | 213 | $55.9K |
| Aug 6, 2026 | Knell Michael Gunnar SVP, Finance and CAO | Sale | 901 | $234.8K |
| Aug 6, 2026 | Knell Michael Gunnar SVP, Finance and CAO | Sale | 810 | $211.8K |
| Aug 5, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Sale 10b5-1 plan | 5,046 | $1.33M |
| Jun 29, 2026 | FOSTER JAMES C Director | Sale 10b5-1 plan | 75,000 | $16.88M |
| Jun 5, 2026 | Girshick Birgit Chief Executive Officer | Gift | 3,386 | $0 |
| Jun 5, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Gift | 1,529 | $0 |
| Jun 5, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Gift | 1,529 | $0 |
| Jun 5, 2026 | FOSTER JAMES C Director | Gift | 10,000 | $0 |
| Jun 5, 2026 | FOSTER JAMES C Director | Gift | 20,000 | $0 |
| Jun 5, 2026 | FOSTER JAMES C Director | Gift | 10,000 | $0 |
| Jun 5, 2026 | FOSTER JAMES C Director | Gift | 153,361 | $0 |
| Jun 5, 2026 | FOSTER JAMES C Director | Gift | 20,000 | $0 |
| Jun 5, 2026 | FOSTER JAMES C Director | Gift | 153,361 | $0 |
| Jun 5, 2026 | Girshick Birgit Chief Executive Officer | Gift | 3,386 | $0 |
| Jun 2, 2026 | Barg Steven Director | Award | 422 | $73.8K |
| May 31, 2026 | Girshick Birgit Chief Executive Officer | Tax withheld | 378 | $68.3K |
| May 31, 2026 | Knell Michael Gunnar SVP, Finance and CAO | Tax withheld | 48 | $8.7K |
| May 31, 2026 | LaPlume Joseph W EVP, Corp Strategy & Develop | Tax withheld | 235 | $42.5K |
| May 31, 2026 | Creamer Victoria L EVP & Chief People Officer | Tax withheld | 194 | $35.1K |
| May 31, 2026 | Mintz Mark EVP, Chief Information Officer | Tax withheld | 64 | $11.6K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Free account. Everything above stays public.
Write why you follow CHARLES RIVER LABORATORIES INTERNATIONAL, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading